Piper Sandler analyst David Westenberg reiterates an Overweight rating on Illumina with a $290 price target after the Wall Street Journal reported that Carl Icahn is preparing a proxy fight with the company. The analyst agrees with Icahn that the base business of llumina is substantially undervalued and that the removal of Grail would help investors better conceptualize just how strong the base asset is. Piper says Icahn’s primary mission sounds like a Grail divestiture. It thinks investors focusing on the core asset of Illumina without Grail will drive upside to the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ILMN:
- Billionaire Carl Icahn Could Lock Horns with Illumina (NASDAQ:ILMN)
- Icahn planning proxy fight at Illumina, WSJ reports
- Myriad Genetics, Illumina expand partnership for HRD testing access
- Illumina and Myriad Genetics partner for HRD testing in the U.S.
- Illumina price target lowered to $240 from $255 at UBS